Payment overview · 2025
General Payments
$279.43
9 reported records · 7 companies
Healthcare provider profile · identity verified
Gregory Thomas Valainis, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SPARTANBURG, SC · NPI 1215906151
Verified facts
What the public records show
CMS Open Payments records show Gregory Thomas Valainis, MD received $279.43 in general payments during 2025 across 9 reported records.
Gilead Sciences, Inc. accounted for 28.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Biktarvy, Mounjaro.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Descovy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $79.86 | 28.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $79.66 | 28.5% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $41.37 | 14.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $24.36 | 8.7% | 1 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $20.78 | 7.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.43 | 6.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.97 | 5.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $279.43 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $79.66 | 1 | 2025 |
Source payment records
|
|||||
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $64.44 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $24.36 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc. | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc. | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.97 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.97 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 74 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
74 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
68 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 373 | 115 |
| Amlodipine Besylate | Amlodipine Besylate | 251 | 68 |
| Losartan Potassium | Losartan Potassium | 218 | 62 |
| Omeprazole | Omeprazole | 216 | 54 |
| Lisinopril | Lisinopril | 215 | 59 |
| Trazodone Hcl | Trazodone Hcl | 214 | 52 |
| Gabapentin | Gabapentin | 201 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 188 | 55 |
| Pravastatin Sodium | Pravastatin Sodium | 182 | 51 |
| Metformin Hcl | Metformin Hcl | 176 | 48 |
| Levothyroxine Sodium | Levothyroxine Sodium | 158 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 148 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 133 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 126 | 30 |
| Finasteride | Finasteride | 106 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 106 | 32 |
| Carvedilol | Carvedilol | 102 | 31 |
| Sertraline Hcl | Sertraline Hcl | 96 | 19 |
| Potassium Chloride | Potassium Chloride | 95 | 28 |
| Ozempic | Semaglutide | 90 | 19 |
| Alendronate Sodium | Alendronate Sodium | 88 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 84 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 78 | 23 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 74 | suppressed |
| Ezetimibe | Ezetimibe | 73 | 22 |
| Simvastatin | Simvastatin | 70 | 20 |
| Glipizide | Glipizide | 69 | 25 |
| Eliquis | Apixaban | 68 | 16 |
| Prezcobix | Darunavir/Cobicistat | 67 | suppressed |
| Allopurinol | Allopurinol | 66 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 66 | 21 |
| Buspirone Hcl | Buspirone Hcl | 61 | 12 |
| Meloxicam | Meloxicam | 59 | 18 |
| Spironolactone | Spironolactone | 57 | 20 |
| Tramadol Hcl | Tramadol Hcl | 56 | 21 |
| Doxazosin Mesylate | Doxazosin Mesylate | 55 | 12 |
| Januvia | Sitagliptin Phosphate | 55 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | 12 |
| Glimepiride | Glimepiride | 53 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 52 | 11 |
| Tivicay | Dolutegravir Sodium | 51 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 47 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 16 |
| Chlorthalidone | Chlorthalidone | 45 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 15 |
| Famotidine | Famotidine | 42 | 11 |
| Furosemide | Furosemide | 42 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 42 | 13 |
| Propranolol Hcl | Propranolol Hcl | 42 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 39 | 13 |
| Montelukast Sodium | Montelukast Sodium | 39 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 38 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | 12 |
| Atenolol | Atenolol | 37 | suppressed |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 11 |
| Glipizide Er | Glipizide | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Temazepam | Temazepam | 28 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 27 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 15 |
| Colchicine | Colchicine | 25 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 25 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 25 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Isentress | Raltegravir Potassium | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 23 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Invokana | Canagliflozin | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Ritonavir | Ritonavir | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 16 | suppressed |
| Indapamide | Indapamide | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Rukobia | Fostemsavir Tromethamine | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Edurant | Rilpivirine Hcl | 13 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Rezdiffra | Resmetirom | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Dovato | Dolutegravir Sodium/Lamivudine | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Prezista | Darunavir | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Darunavir | Darunavir | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 11 | suppressed |
| Leflunomide | Leflunomide | 11 | suppressed |
| Maraviroc | Maraviroc | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Ramelteon | Ramelteon | 11 | suppressed |
| Rifampin | Rifampin | 11 | suppressed |
| Sulindac | Sulindac | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $279.43 · 9 records | Gilead Sciences, Inc. | ABRYSVO, Biktarvy, COMIRNATY, CT THROMBECTOMY SYSTEM KIT, FLOWTRIEVER CATHETER, S, MOUNJARO, PREVNAR 20, REXULTI, The Cologuard Plus Collection Kit, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Biktarvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Gilead Sciences, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error